Astrocyte Reactivity Mechanism

Astrocyte Reactivity in Neurodegeneration

Overview

Astrocyte reactivity (also termed astrogliosis) is a hallmark response of astrocytes to central nervous system injury, infection, or neurodegeneration[@liddelow2020] PMID: 39979986. This complex cellular process involves dramatic changes in astrocyte morphology, gene expression, and function, positioning reactive astrocytes as critical players in both protective and pathogenic aspects of neurological disease[@escott2023] PMID: 37679321. While reactive astrocytes initially attempt to contain damage and maintain homeostasis, chronic activation contributes to neuroinflammation, synaptic dysfunction, and disease progression in Alzheimer's Disease (AD)[@astrocytes2023], Parkinson's Disease (PD)[@booth2023], amyotrophic lateral sclerosis (ALS)[@maniatis2022], Huntington's disease[@wander2023], and multiple sclerosis[@ponath2023] PMID: 37308616.

Astrocyte Reactivity in Neurodegeneration

Overview

Astrocyte reactivity (also termed astrogliosis) is a hallmark response of astrocytes to central nervous system injury, infection, or neurodegeneration[@liddelow2020] PMID: 39979986. This complex cellular process involves dramatic changes in astrocyte morphology, gene expression, and function, positioning reactive astrocytes as critical players in both protective and pathogenic aspects of neurological disease[@escott2023] PMID: 37679321. While reactive astrocytes initially attempt to contain damage and maintain homeostasis, chronic activation contributes to neuroinflammation, synaptic dysfunction, and disease progression in Alzheimer's Disease (AD)[@astrocytes2023], Parkinson's Disease (PD)[@booth2023], amyotrophic lateral sclerosis (ALS)[@maniatis2022], Huntington's disease[@wander2023], and multiple sclerosis[@ponath2023] PMID: 37308616.

Astrocytes are the most abundant glial cell type in the mammalian brain, comprising approximately 20-40% of cortical cells[@eyal2022]. These star-shaped cells perform essential homeostatic functions that include regulation of extracellular ion concentrations, maintenance of the blood-brain barrier (BBB), provision of metabolic support to neurons, recycling of neurotransmitters, and modulation of synaptic transmission through the release of gliotransmitters[@bekku2022]. In response to injury or disease, astrocytes undergo a transformation characterized by cellular hypertrophy, proliferation, and altered gene expression—a process collectively termed astrocyte reactivity or astrogliosis[@pekny2022].

The concept of astrocyte reactivity has evolved considerably over the past decade. Historically viewed as a uniform response to CNS insult, it is now recognized that reactive astrocytes represent a heterogeneous population with distinct phenotypic subtypes that can be either neuroprotective or neurotoxic depending on the context[@miller2022]. This dichotomy has profound implications for understanding disease mechanisms and developing therapeutic interventions targeting astrocyte dysfunction. The recognition that astrocytes exist on a spectrum of activation states rather than simply being "resting" or "reactive" has fundamentally changed how we conceptualize their roles in neurological disorders.

The historical perspective on astrocyte reactivity spans over a century of scientific investigation. Early neuroanatomists, using classical histological staining techniques, observed morphological changes in astrocytes surrounding brain lesions, terming this response "Reaktionen der Astroglia" or " gliose." The development of immunohistochemistry for [GFAP](/entities/gfap) in the 1970s enabled more precise characterization of astrocyte responses, revealing the complexity of astroglial reactions to various CNS insults. However, the advent of transcriptomic technologies in the 2010s provided the critical breakthrough that allowed researchers to molecularly define distinct reactive astrocyte phenotypes, leading to the identification of the neurotoxic A1 and neuroprotective A2 subtypes that form the foundation of our current understanding.

Reactive Astrocyte States

A1 (Neurotoxic) Phenotype

The identification of distinct reactive astrocyte phenotypes represents a major advance in understanding astrocyte biology[@liddelow2015]. The A1 phenotype, characterized by its neurotoxic properties, is induced primarily by pro-inflammatory microglia:

Inducing Factors: The A1 phenotype is triggered by a combination of factors released from activated microglia, specifically interleukin-1 alpha (IL-1α), tumor necrosis factor (TNF), and complement component C1q[@brennan2015]. These molecules act on astrocytes through their respective receptors, initiating intracellular signaling cascades that drive the transcriptional changes characteristic of the A1 state. The precise combination of these three factors is critical, as individual cytokines alone are insufficient to fully induce the A1 phenotype, highlighting the complexity of microglial-astrocytic crosstalk in regulating astrocyte reactivity.

Marker Genes: Transcriptomic analyses have identified a panel of genes specifically upregulated in A1 astrocytes[@zamanian2022]. Key markers include:

• Ggta1 (glycosyltransferase): Involved in ganglioside metabolism
• C3 (complement component 3): Central driver of synapse elimination
• Serpina3n (serine protease inhibitor): Modulates neuroinflammation
• Lif (leukemia inhibitory factor): Cytokine with multiple effects on glia
• Hk1 (hexokinase 1): Metabolic reprogramming
• Fcrls (Fc receptor-like S): Immune-related function

• Loss of protective functions (reduced K⁺ buffering, impaired glutamate uptake)
• Gain of toxic functions (complement-mediated synapse elimination)
• Secretion of factors that kill neurons and oligodendrocytes
• Promotion of ongoing neuroinflammation

Disease Association: A1 astrocytes have been identified in human brain tissue from patients with AD, PD, ALS, Huntington's disease, and multiple sclerosis[@yang2022]. Their presence correlates with regions of neuronal loss, suggesting a direct contribution to disease pathogenesis. In AD, A1 astrocytes are particularly abundant in regions with high amyloid burden, while in PD, they surround the substantia nigra pars compacta where dopaminergic neurons are lost. The widespread presence of A1 astrocytes across neurodegenerative diseases suggests that this reactive phenotype represents a common pathological mechanism that could be targeted therapeutically.

A2 (Neuroprotective) Phenotype

In contrast to A1 astrocytes, the A2 phenotype is associated with tissue repair and neuroprotection[@zhao2022]:

Inducing Factors: A2 astrocytes are induced by ischemia, spinal cord injury, and other forms of acute CNS damage[@jiang2022]. Key inducing cytokines include interleukin-6 (IL-6), ciliary neurotrophic factor (CNTF), and leukemia inhibitory factor (LIF), which activate the JAK-STAT signaling pathway. The contextual nature of A2 induction is important—aspects of the injury microenvironment, including the temporal profile of cytokine release and the presence of growth factors, influence whether astrocytes adopt an A2 phenotype.

Marker Genes: A2 astrocytes express a distinct set of genes associated with repair functions[@sofroniew2022]:

• S100a10 (S100 calcium-binding protein): Involved in cell proliferation and migration
• Ptx3 (pentraxin 3): Acute phase protein with anti-inflammatory properties
• Tm4sf1 (transmembrane 4 L six family member 1): Cell surface receptor involved in repair
• Cd109: Promotes tissue remodeling
• Clcf1 (cardiotrophin-like cytokine factor 1): Neuroprotective signaling
• Bdnf (brain-derived neurotrophic factor): Trophic support

• Enhanced support of neuronal metabolism
• Promotion of synapse formation and repair
• Secretion of trophic factors
• Modulation of inflammation toward resolution

Therapeutic Implications: Understanding the mechanisms driving A1 versus A2 polarization offers opportunities for therapeutic intervention. Strategies that suppress A1 formation or promote conversion to A2 phenotype could have broad neuroprotective effects[@converting2023]. The reversible nature of astrocyte polarization suggests that therapeutic modulation of astrocyte phenotype is feasible, offering hope for disease-modifying treatments.

Molecular Mechanisms

Signaling Pathways

Reactive astrocytes are regulated by multiple intracellular signaling pathways that integrate signals from the microenvironment[@chen2022]:

NF-κB Pathway: Nuclear factor kappa B (NF-κB) is a master regulator of inflammatory responses in astrocytes[@jang2022]. Activated by TNF, IL-1β, and pathogen-associated molecular patterns (PAMPs), NF-κB translocation to the nucleus drives expression of pro-inflammatory genes including cytokines (IL-6, IL-1β, TNF-α), chemokines (CCL2, CXCL1), and inducible enzymes (COX-2, iNOS)[@brambilla2022]. The NF-κB pathway exists in multiple isoforms, with p65/p50 heterodimers being the most prevalent in astrocytes. Constitutive NF-κB activity in reactive astrocytes contributes to chronic neuroinflammation, making this pathway an attractive therapeutic target.

JAK/STAT Pathway: The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway mediates cytokine-driven astrocyte responses[@he2022]. Activation by IL-6, CNTF, and LIF promotes the A2 phenotype through STAT3 phosphorylation and nuclear translocation[@sato2022]. This pathway also plays important roles in astrocyte proliferation and scar formation. The JAK/STAT pathway demonstrates the contextual nature of astrocyte signaling—while it promotes neuroprotective A2 responses to certain cytokines, dysregulated activation can contribute to pathological outcomes.

MAPK Pathways: Mitogen-activated protein kinase (MAPK) cascades regulate astrocyte responses to stress[@waetzig2022]. The three major MAPK pathways—ERK, JNK, and p38—have distinct but overlapping functions:

• ERK: Cell survival, proliferation, and differentiation
• JNK: Apoptosis and stress response
• p38: Inflammatory signaling and cytokine production

Key Effectors

Cytokines: Reactive astrocytes produce and respond to a diverse array of cytokines[@choi2022]:

Pro-inflammatory cytokines:

• IL-1β: Potent inducer of astrogliosis, synergizes with TNF
• IL-6: Pleiotropic effects on astrocyte proliferation and function
• TNF-α: Promotes A1 phenotype, disrupts glutamate transport

• IL-10: Suppresses inflammatory responses
• TGF-β: Regulates astrocyte proliferation and scar formation

• CCL2 (MCP-1): Recruits monocytes and microglia
• CXCL1 (GRO-α): Attracts neutrophils and promotes inflammation

• C3: The hallmark A1 astrocyte marker, drives complement-mediated synapse elimination
• C1q: Initiates classical complement cascade, tags synapses for removal
• C4: Associated with synaptic pruning during development and disease

• Kir4.1: Inwardly rectifying potassium channel, reduced in AD and ALS
• EAAT1/EAAT2: Excitatory amino acid transporters, impaired glutamate clearance
• AQP4: Aquaporin-4 water channel, mislocalized in various conditions

Disease-Specific Roles

Alzheimer's Disease

Astrocytes in AD exhibit complex, often contradictory roles that evolve throughout disease progression[@kulijewicznagrny2022]:

Reactive Astrocytes Around Amyloid Plaques: Amyloid plaques in AD brain are surrounded by astrocytes that attempt to contain and clear Aβ[@wysscoray2022]:

• Reactive astrocytes upregulate Aβ-binding receptors (LRP1, RAGE) for enhanced uptake
• ApoE and clusterin secretion promotes Aβ clearance through glial pathways
• Astrocytes can internalize and degrade Aβ under certain conditions
• However, astrocyte dysfunction may also promote plaque formation through Aβ nucleation on astrocyte processes

Metabolic Dysfunction: AD astrocytes show impaired metabolic support to neurons[@sal2022]:

• Reduced lactate production compromises neuronal energy supply
• Impaired glucose uptake and metabolism
• Disrupted astrocyte-neuron lactate shuttle
• Loss of metabolic coupling contributing to hypometabolism observed in AD

Ion Homeostasis Disruption: Reactive astrocytes in AD have altered ion channel expression[@nwaobi2022a]:

• Reduced Kir4.1 leads to impaired K⁺ buffering
• Disruption of extracellular K⁺ regulation affects neuronal excitability
• Altered Ca²⁺ signaling affects gliotransmitter release
• Impaired water homeostasis through AQP4 mislocalization

• Reduced EAAT1/EAAT2 expression decreases glutamate uptake
• Excessive glutamate in extracellular space contributes to excitotoxicity
• Impaired GABA recycling affects inhibitory neurotransmission
• Dysregulated glutamine synthesis affects both glutamate and GABA synthesis

Parkinson's Disease

Astrocytes contribute to PD pathogenesis through multiple mechanisms[@mguara2023]:

Reactive Astrocytes in Substantia Nigra: The substantia nigra pars compacta shows prominent astrocyte reactivity in PD brain[@maarouf2022]:

• Reactive astrocytes cluster around remaining dopaminergic neurons
• Astrocyte hypertrophy precedes detectable neuronal loss in some models
• GFAP upregulation correlates with disease severity
• Loss of neurotrophic factor support from astrocytes

α-Synuclein Interactions: Astrocytes play complex roles in α-synuclein pathology[@braak2022]:

• Astrocytes can take up extracellular α-syn through endocytosis
• Astrocytic accumulation of α-syn impairs cellular function
• α-syn-containing astrocytes may propagate pathology to neurons
• Astrocyte-to-neuron transmission of α-syn contributes to disease spread

Mitochondrial Dysfunction: Astrocyte mitochondria are affected in PD[@cortassa2022]:

• Complex I deficiency observed in PD astrocytes
• Impaired mitochondrial respiration affects ATP production
• Reduced ability to support neuronal metabolic needs
• Contribution to astrocyte-neuron metabolic coupling deficits

• Persistent production of pro-inflammatory cytokines
• Chemokine release attracts activated microglia
• Feedback loops between astrocytes and microglia amplify inflammation
• Therapeutic targeting of astrocyte inflammation shows promise in models

Amyotrophic Lateral Sclerosis

In ALS, astrocyte dysfunction is a critical contributor to motor neuron vulnerability[@rothstein2022]:

Non-Cell Autonomous Toxicity: Astrocytes expressing mutant SOD1 contribute to motor neuron death[@di2022]:

• Mutant SOD1 astrocytes release toxic factors
• Impaired glutamate transport increases excitotoxicity
• Reduced support of motor neuron survival
• Astrocyte-specific SOD1 knockdown slows disease progression

Glutamate Excitotoxicity: ALS astrocytes show impaired glutamate handling[@rothstein2022a]:

• Reduced EAAT2 (GLT-1) expression decreases glutamate uptake
• Elevated extracellular glutamate contributes to motor neuron death
• Loss of astrocytic glutamate buffering capacity
• Correlation between EAAT2 loss and disease severity

Failed Supportive Functions: ALS astrocytes lose essential supportive properties[@van2022]:

• Impaired potassium buffering affects motor neuron excitability
• Reduced metabolic support compromises neuronal health
• Diminished trophic factor secretion (BDNF, GDNF)
• Disrupted astrocyte-neuron communication

Therapeutic Targets

Understanding astrocyte biology has opened new therapeutic avenues for neurodegenerative diseases[@stout2022]:

Modulating Astrocyte Polarization

A1 to A2 Conversion: Strategies to shift astrocyte phenotype from neurotoxic A1 to protective A2[@coulter2022]:

• CNTF delivery promotes A2 polarization
• IL-10 overexpression suppresses A1 genes
• JAK/STAT pathway modulation
• PPARγ agonists influence astrocyte phenotype

Preventing A1 Formation: Blocking the signals that drive A1 phenotype[^48]:

• Neutralizing antibodies against IL-1α, TNF, C1q
• Inhibition of microglial activation
• Complement pathway inhibitors

Enhancing Protective Functions

Metabolic Support: Improving astrocyte metabolism to better support neurons[@pellerin2022]:

• Lactate supplementation or enhanced lactate shuttle
• Glucose transporter modulators
• Mitochondrial function enhancers
• Metabolic coupling restoration

• BDNF delivery or expression enhancers
• GDNF family ligands
• CNTF and related cytokines
• Trophic factor combination approaches

Reducing Toxicity

Complement Inhibition: Targeting the complement-mediated synapse elimination[@stevens2022]:

• Anti-C3 therapies
• C1q neutralizing antibodies
• Complement receptor antagonists
• Downstream complement inhibitors

• Kir4.1 channel openers
• EAAT2 expression enhancers
• AQP4 normalization
• Calcium channel modulators

Astrocyte-Neuron Communication

Gliotransmission

Astrocytes communicate with neurons through release of gliotransmitters[@araque2022]:

Glutamate Release: Astrocytic glutamate modulates synaptic transmission[@parpura2022]:

• Ca²⁺-dependent glutamate release
• Regulation of NMDA and AMPA receptor activity
• Control of synaptic plasticity
• Pathological release in disease states

• Activity-dependent release
• Regulation of synaptic plasticity and memory
• Impaired D-serine signaling in AD
• Therapeutic potential of D-serine modulation

• P2X and P2Y receptor activation
• Conversion to adenosine modulates receptors
• Regulation of sleep-wake cycles
• Involvement in neuropathic pain

Metabolic Coupling

The astrocyte-neuron metabolic unit is essential for brain function[@pellerin2022a]:

Astrocyte-Neuron Lactate Shuttle (ANLS): Astrocytes provide lactate as an energy substrate[@van2022a]:

• Glycolysis in astrocytes produces lactate
• Monocarboxylate transporters (MCTs) mediate lactate transfer
• Neurons oxidize lactate for energy
• ANLS supports synaptic activity and memory formation

• Breakdown supports active neurons during stress
• Lactate release during stimulation
• Impaired glycogen metabolism in disease states
• Therapeutic targeting of glycogenolysis

Astrocyte Reactivity in Aging

Aging is associated with changes in astrocyte function that may predispose to neurodegeneration[@palmer2022]:

Inflammaging: Aged astrocytes show a pro-inflammatory bias[^61]:

• Baseline NF-κB activation
• Elevated cytokine production
• Reduced anti-inflammatory capacity
• Contribution to age-related neuroinflammation

Cellular Senescence: Senescent astrocytes accumulate with age[@he2022a]:

• Senescence-associated secretory phenotype (SASP)
• Persistent pro-inflammatory signaling
• Impaired function and regenerative capacity
• Clearance of senescent astrocytes as therapeutic strategy

Dystrophic Changes: Age-related alterations in astrocyte morphology[@robillard2022]:

• Reduced complexity of processes
• Impaired synaptic coverage
• Altered calcium signaling
• Decreased homeostatic capacity

Research Methods and Tools

Astrocyte Isolation and Culture

Studying astrocytes requires specialized techniques[@foo2022]:

Primary Astrocyte Culture: Dissociated brain tissue allows astrocyte expansion[@saas2022]:

• Differential adhesion for purification
• Serum-containing versus defined media
• Generation of pure astrocyte populations
• Limitations of in vitro astrocyte biology

• Differentiation protocols for astrocytes
• Disease modeling in patient-derived cells
• Applications for drug screening
• Advantages over rodent primary cultures

Astrocyte Markers and Identification

Specific markers enable astrocyte identification and study[@cahoy2022]:

Classical Markers:

• GFAP (glial fibrillary acidic protein): Intermediate filament
• [S100B](/entities/s100b) (S100 calcium-binding protein beta): Calcium-binding protein
• ALDH1L1 (aldehyde dehydrogenase 1 family member L1): Metabolic enzyme

• EAAT1/GLAST and EAAT2/GLT1: Glutamate transporters
• Kir4.1: Potassium channel
• [AQP4](/entities/aqp4): Water channel

• C3: A1 phenotype marker
• Serpina3n: A1 marker in mice
• S100a10, Ptx3: A2 markers

Imaging Techniques

Advanced imaging reveals astrocyte structure and function[@nimmerjahn2022]:

Two-Photon Microscopy: In vivo imaging of astrocyte calcium dynamics[@stowell2022]:

• Ca²⁺ indicator loading
• Astrocyte-specific expression of GCaMP
• Monitoring astrocyte activity in living brain
• Correlation with behavior

• Synaptic coverage analysis
• Process morphology assessment
• Organelle visualization
• Three-dimensional reconstruction

Animal Models of Astrocyte Reactivity

Studying astrocyte reactivity in vivo requires sophisticated animal models that recapitulate key features of human neurodegenerative diseases. Genetic mouse models incorporating disease-causing mutations have provided critical insights into astrocyte contributions to neurodegeneration, while advanced techniques enabling astrocyte-specific manipulation have transformed our ability to test causal relationships.

Genetic Mouse Models: Transgenic mice expressing mutant proteins associated with neurodegenerative diseases have revealed astrocyte involvement in disease pathogenesis. APP/PS1 mice modeling AD show age-dependent astrocyte reactivity around amyloid plaques, with progressive changes in gene expression patterns that mirror human disease. Similarly, mutant SOD1 transgenic mice, the most widely used model of ALS, demonstrate that astrocytes expressing the disease-causing mutation contribute to motor neuron toxicity through non-cell autonomous mechanisms[^71].

Astrocyte-Specific Genetic Manipulation: Technologies enabling astrocyte-specific gene targeting have resolved critical questions about astrocyte roles in neurodegeneration. Cre-lox systems driving recombination under astrocyte promoters such as GFAP or ALDH1L1 allow conditional knockout of disease-relevant genes specifically in astrocytes[^72]. These approaches have demonstrated that removing mutant SOD1 from astrocytes slows disease progression in ALS models, confirming the causal contribution of astrocyte dysfunction.

Chemogenetic and Optogenetic Control: Designer receptors exclusively activated by designer drugs (DREADDs) and light-sensitive channels enable functional manipulation of astrocyte activity in vivo[^73]. Activation of Gq-coupled DREADDs in astrocytes increases intracellular calcium and gliotransmitter release, allowing investigation of how astrocyte activity influences neuronal function and behavior. Conversely, inhibitory DREADDs enable suppression of astrocyte reactivity to test therapeutic strategies.

Emerging Research and Future Directions

The field of astrocyte biology continues to evolve rapidly, with several emerging areas offering new insights into astrocyte roles in neurodegeneration and potential therapeutic approaches. Single-cell transcriptomics has revealed unprecedented heterogeneity in reactive astrocytes, suggesting that the binary A1/A2 classification represents an oversimplification of the true complexity of astrocyte responses. Future research will need to account for this diversity and develop approaches to manipulate specific astrocyte subpopulations.

Astrocyte Heterogeneity: Emerging evidence indicates that astrocyte reactivity encompasses multiple distinct states beyond the A1/A2 dichotomy. Single-nucleus RNA sequencing of human brain tissue has identified region-specific astrocyte populations with unique transcriptional signatures[^74]. Understanding this heterogeneity and its functional significance represents a major challenge for the field. The development of spatial transcriptomics techniques allowing assessment of astrocyte gene expression in situ will be critical for relating molecular heterogeneity to anatomical patterns of neurodegeneration.

Astrocytes in Blood-Brain Barrier Maintenance: The role of astrocytes in maintaining and regulating the BBB has gained attention as a potential therapeutic target[^75]. Astrocyte end-feet ensheath cerebral blood vessels and release factors that regulate endothelial tight junction formation and function. In neurodegeneration, astrocyte dysfunction may contribute to BBB breakdown, allowing peripheral immune cell entry and exacerbating neuroinflammation. Therapeutic strategies aimed at preserving astrocyte-mediated BBB support represent an emerging approach.

Astrocyte Metabolism as Therapeutic Target: Given the central role of metabolic dysfunction in neurodegenerative diseases, astrocyte metabolism has emerged as a promising therapeutic target[^76]. Strategies to enhance astrocyte glycolysis, improve lactate shuttle function, or restore mitochondrial health in astrocytes could preserve metabolic support to neurons. The development of astrocyte-targeted drug delivery systems offers potential for achieving these goals while minimizing off-target effects.

Conclusion

Astrocyte reactivity is a fundamental response to CNS injury and disease that plays critical roles in neurodegenerative disorders. The recognition of distinct reactive phenotypes—neurotoxic A1 and neuroprotective A2—has transformed our understanding of astrocyte biology and opened new therapeutic possibilities. In Alzheimer's Disease, Parkinson's Disease, and ALS, astrocyte dysfunction contributes to disease progression through multiple mechanisms including loss of supportive functions, gain of toxic properties, and propagation of neuroinflammation. Therapeutic strategies targeting astrocyte reactivity offer promise for disease modification in these devastating disorders.

The journey from viewing astrocytes as passive support cells to recognizing them as active participants in neurological disease pathogenesis represents a major shift in neuroscience. As our understanding of astrocyte biology continues to deepen, so too will our ability to develop effective therapies targeting these essential cells. The near-term goals of converting neurotoxic A1 astrocytes to protective A2 phenotypes, enhancing astrocyte metabolic support, and reducing complement-mediated toxicity represent viable paths toward clinical translation. However, the complexity of astrocyte functions and the heterogeneity of their reactive states underscore the need for continued basic research to inform therapeutic development.

Future studies will benefit from improved experimental models, including human iPSC-derived astrocytes and advanced imaging technologies that enable longitudinal monitoring of astrocyte responses in living brain. Integration of computational approaches with experimental data will accelerate identification of therapeutic targets and prediction of treatment outcomes. The ultimate goal of preserving neuronal function and preventing irreversible degeneration in neurodegenerative diseases may well depend on our ability to understand and manipulate astrocyte reactivity.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/als)
• [Frontotemporal Dementia](/diseases/ftd)
• [Microglial Activation](/mechanisms/microglial-activation)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Tauopathies](/mechanisms/tauopathies)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Tau Protein](/proteins/tau-protein)
• [Astrocytes](/cell-types/astrocytes)
• [Oligodendrocytes](/cell-types/oligodendrocytes)
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier-dysfunction)
• [Excitotoxicity](/mechanisms/excitotoxicity)
• [Neurovascular Coupling](/mechanisms/neurovascular-coupling)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

• PMID: 37679321 Astrocyte reactivity and inflammation-induced depression-like behaviors are regulated by Orai1 calcium channels. (2023; Nat Commun)
• PMID: 37308616 Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration. (2023; Nat Rev Neurol)
• PMID: 39979986 Mechanisms of astrocyte aging in reactivity and disease. (2025; Mol Neurodegener)